source
- Arvinas CEO outlines strategy to rebuild pipeline after lead asset departureIn a recent episode of the Denatured podcast, Arvinas President and CEO Randy Teel discussed how the company is shifting focus to an early‑stage pipeline after its lead asset was out‑licensed or di…
- FDA advisory panel reviews Replimune's experimental melanoma therapy RP1STAT is live-blogging an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting that convened on Thursday to examine Replimune's engineered viral immunotherapy RP1 for melanoma. The p…